Literature DB >> 11468548

Patterns of engraftment in different strains of immunodeficient mice reconstituted with human peripheral blood lymphocytes.

T Berney1, R D Molano, A Pileggi, P Cattan, H Li, C Ricordi, L Inverardi.   

Abstract

BACKGROUND: Models of immunodeficient mice reconstituted with a competent human immune system would represent an invaluable tool for the study of transplantation immunobiology allergy, autoimmunity, and infectious diseases. Severe combined immune deficiency (scid) mice can be successfully reconstituted with human peripheral blood lymphocytes (PBLs), but rates and levels of engraftment are poor. New strains of mice with diverse immunodeficiencies have been recently characterized or developed, which might prove to be advantageous for in vivo studies of human immune reactivity.
METHODS: We have compared rates and patterns of human PBL engraftment in four available immunodeficient murine strains; scid-beige, nonobese diabetic (NOD)-scid, NOD-scid-beta2 m- and rag-. T- and B-lymphocyte engraftment, phenotype of engrafted cells, and occurrence of graft-versus-host disease (GVHD) were studied and compared.
RESULTS: Successful engraftment of human PBL was readily obtained in the majority of scid-beige, NOD-scid, and NOD-scid-beta2 m- with a single i.p. administration of human PBLs, whereas it was seldom achieved in rag- animals. Human Ig levels were accordingly remarkably low in rag- recipients but, interestingly also in NOD-scid-beta2 m- mice. Engraftment was readily observed not only in peripheral blood but also in spleen and bone marrow of successfully reconstituted animals. Phenotypic analysis of engrafted human cells showed preserved CD4/CD8 ratios and a clear skewing toward an activated phenotype. GVHD was invariably observed in successfully reconstituted animals.
CONCLUSIONS: Our data indicate that a high rate of reconstitution with human lymphocytes can be achieved in scid-beige, NOD-scid, and NOD-scid-beta2 m- mice. Human Ig are produced at high levels, except in NOD-scid-beta2 m-, including xenoreactive natural antibodies. Scid-beige and NOD-scid appear therefore better suited than NOD-scid-beta2 m- or rag- for analysis of human immunoreactivity in vivo. An important caveat is the invariable occurrence of GVHD that precludes long-term studies in this model system.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11468548     DOI: 10.1097/00007890-200107150-00026

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  10 in total

1.  Update of humanized animal disease models in studying Graft-versus-host disease.

Authors:  Feng Huang; Feng Lin Cao; Song Guo Zheng
Journal:  Hum Vaccin Immunother       Date:  2018-09-05       Impact factor: 3.452

2.  Immunoregulation of a CB2 receptor agonist in a murine model of neuroAIDS.

Authors:  Santhi Gorantla; Edward Makarov; Deepa Roy; Jennifer Finke-Dwyer; L Charles Murrin; Howard E Gendelman; Larisa Poluektova
Journal:  J Neuroimmune Pharmacol       Date:  2010-06-12       Impact factor: 4.147

3.  Factors affecting human T cell engraftment, trafficking, and associated xenogeneic graft-vs-host disease in NOD/SCID beta2mnull mice.

Authors:  Bruno Nervi; Michael P Rettig; Julie K Ritchey; Hanlin L Wang; Gerhard Bauer; Jon Walker; Mark L Bonyhadi; Ronald J Berenson; Julie L Prior; David Piwnica-Worms; Jan A Nolta; John F DiPersio
Journal:  Exp Hematol       Date:  2007-08-30       Impact factor: 3.084

4.  Experimental endometriosis in immunocompromised mice after adoptive transfer of human leukocytes.

Authors:  Kaylon L Bruner-Tran; Alessandra C Carvalho-Macedo; Antoni J Duleba; Marta A Crispens; Kevin G Osteen
Journal:  Fertil Steril       Date:  2009-07-15       Impact factor: 7.329

5.  Reduction of human anti-tetanus toxoid antibody in hu-PBL-SCID mice by immunodominant peptides of tetanus toxoid.

Authors:  D J Jackson; C J Elson; B M Kumpel
Journal:  Clin Exp Immunol       Date:  2004-08       Impact factor: 4.330

6.  Evaluation of the tolerogenic effects of donor bone marrow cells using a severe combined immunodeficient mouse-human islet transplant model.

Authors:  James M Mathew; Bonnie Blomberg; Camillo Ricordi; Violet Esquenazi; Joshua Miller
Journal:  Hum Immunol       Date:  2008-08-12       Impact factor: 2.850

7.  Human anti-CCR4 minibody gene transfer for the treatment of cutaneous T-cell lymphoma.

Authors:  Thomas Han; Ussama M Abdel-Motal; De-Kuan Chang; Jianhua Sui; Asli Muvaffak; James Campbell; Quan Zhu; Thomas S Kupper; Wayne A Marasco
Journal:  PLoS One       Date:  2012-09-04       Impact factor: 3.240

8.  Human BLyS facilitates engraftment of human PBL derived B cells in immunodeficient mice.

Authors:  Madelyn R Schmidt; Michael C Appel; Lisa J Giassi; Dale L Greiner; Leonard D Shultz; Robert T Woodland
Journal:  PLoS One       Date:  2008-09-11       Impact factor: 3.240

9.  Immunoglobulin-like transcript 3-Fc suppresses T-cell responses to allogeneic human islet transplants in hu-NOD/SCID mice.

Authors:  George Vlad; Vivette D D'Agati; Qing-Yin Zhang; Zhuoru Liu; Eric K Ho; Thalachallour Mohanakumar; Mark A Hardy; Raffaello Cortesini; Nicole Suciu-Foca
Journal:  Diabetes       Date:  2008-04-16       Impact factor: 9.461

Review 10.  Mouse models with human immunity and their application in biomedical research.

Authors:  Baojun Zhang; Ziyuan Duan; Yong Zhao
Journal:  J Cell Mol Med       Date:  2008-04-15       Impact factor: 5.310

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.